Two HCV Treatments to Be Discontinued

Two medications for the treatment of hepatitis C, Viekira XR and Technivie, have been discontinued, according to the Food and Drug Administration (FDA). The discontinuation is voluntary and not related to safety, quality, or efficacy of the medications.1,2 Viekira XR and Technivie are both manufactured by AbbVie.

Both products are estimated to be available until January 1, 2019.

What should I know about these medications?

Viekira XR (dasabuvir sodium; ombitasvir; paritaprevir; ritonavir) was approved by the FDA in 2016 for treatment of adults with chronic hepatitis C virus (HCV) genotype 1 who have compensated cirrhosis or do not have cirrhosis at all.

Viekira XR is the extended-release formulation of Viekira Pak, which is currently still available.

Technivie (ombitasvir; paritaprevir; ritonavir) was FDA-approved in 2015 for the treatment of chronic HCV genotype 4 who have compensated cirrhosis or do not have cirrhosis at all. Technivie is indicated for use with ribavirin.

What other treatments are available?

The discontinuation of Viekira XR and Technivie will leave two fewer treatment options of chronic HCV; However, there are several other effective treatment options available.

Treatment options for adults with HCV genotype 1 include:

Treatment options for adults with HCV genotype 4 include:

  • Epclusa
  • Harvoni
  • Mavyret
  • Olysio plus Sovaldi or peginterferon and ribavirin
  • Sovaldi plus ribavirin
  • Technivie – Available until January 1, 2019
  • Zepatier

It’s always important to discuss which treatment is best for you with your doctor or healthcare team.

View References

Comments

Poll